EGFR inhibitor could provide major advance in lung cancer
European Pharmaceutical Review
FEBRUARY 21, 2024
TAGRISSO as a combination treatment with chemotherapy was recently approved in the US, based on data from the FLAURA2 Phase III trial. Research predicts 2029 small molecule oncology market leaders The post EGFR inhibitor could provide major advance in lung cancer appeared first on European Pharmaceutical Review.
Let's personalize your content